Execution of License Agreement on カジノ ディーラーramexaカジノ ディーラー for Tinnitus with Merz Pharmaceuticals for Japan Territory
November 5, 2009
KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Chiyoda-ku, Tokyo, President: Keiji Hirai, Ph.D.), a wholly owカジノ ディーラーd subsidiary of KYORIN Co., Ltd., today entered into a License Agreement for カジノ ディーラーramexaカジノ ディーラー, a tinnitus treatment product currently being developed in the US and Europe, with Merz Pharmaceuticals GmbH ("Merz") (Head office: Frankfurt am Main, Germany, CEO: Martin Zügel, Ph.D.) for the territory of Japan.
Please see the PDF file below for details.
